Nehme Hachem-El

Montreal, QC H3T1C5, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

In vitro inhibition of STAT5 signaling limits CD8⁺ T cell exhaustion and improves outcomes in adoptive T-cell therapy.

In vitro inhibition of STAT5 signaling limits CD8⁺ T cell exhaustion and improves outcomes in adoptive T-cell therapy.

Journal: Cancer immunology research
Published: November 26, 2025

Erratum: A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Erratum: A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Journal: iScience
Published: October 31, 2025

The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.

The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.

Journal: iScience
Published: May 12, 2025

ARM-X: an adaptable mesenchymal stromal cell-based vaccination platform suitable for solid tumors.

ARM-X: an adaptable mesenchymal stromal cell-based vaccination platform suitable for solid tumors.

Journal: Stem cell research & therapy
Published: January 24, 2025

A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Journal: iScience
Published: November 14, 2024

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Journal: iScience
Published: October 28, 2024

Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth.

Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth.

Journal: Journal of translational medicine
Published: February 11, 2024

Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.

Journal: Leukemia
Published: December 12, 2023

A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.

A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.

Journal: iScience
Published: October 10, 2023

Intratumoral administration of unconjugated Accum™ impairs the growth of pre-established solid lymphoma tumors.

Intratumoral administration of unconjugated Accum™ impairs the growth of pre-established solid lymphoma tumors.

Journal: Cancer science
Published: March 31, 2023

CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.

CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216.

Journal: Blood advances
Published: September 08, 2022

The CIt protocol: A blueprint to potentiate the immunogenicity of immunoproteasome-reprogrammed mesenchymal stromal cells.

The CIt protocol: A blueprint to potentiate the immunogenicity of immunoproteasome-reprogrammed mesenchymal stromal cells.

Journal: iScience
Published: July 14, 2022
Showing 1-12 of 54

Last Updated: 09/26/2026